血管免疫母细胞性T细胞淋巴瘤
IDH2型
癌症研究
淋巴瘤
突变
微小残留病
罗亚
血液学
疾病
生物
基因
医学
病理
免疫学
遗传学
白血病
T细胞
IDH1
信号转导
免疫系统
作者
Mamiko Sakata‐Yanagimoto,Rie Nakamoto-Matsubara,Daisuke Komori,Tran B. Nguyen,Keiichiro Hattori,Toru Nanmoku,Takayasu Kato,Naoki Kurita,Yasuhisa Yokoyama,Naoshi Obara,Yuichi Hasegawa,Atsushi Shinagawa,Shigeru Chiba
标识
DOI:10.1007/s00277-017-3038-2
摘要
Recent genetic studies identified that the disease-specific G17V RHOA mutation, together with mutations in TET2, DNMT3A, and IDH2, is a hallmark of angioimmunoblastic T cell lymphomas (AITL). The diagnostic value of these mutations is now being investigated. Circulating tumor DNAs (ctDNAs) may offer a non-invasive testing for diagnosis and disease monitoring of cancers. To investigate whether these mutations are useful markers for ctDNAs in AITL and its related lymphomas, we performed targeted sequencing for TET2, RHOA, DNMT3A, and IDH2 in paired tumors and cell-free DNAs from 14 patients at diagnosis. Eighty-three percent of mutations detected in tumors were also observed in cell-free DNAs. During the disease course, mutations were detectable in cell-free DNAs in a refractory case, while they disappeared in a chemosensitive case. These data suggest that the disease-specific gene mutations serve as sensitive indicators for ctDNAs and may also be applicable for non-invasive monitoring of minimal residual diseases in AITL.
科研通智能强力驱动
Strongly Powered by AbleSci AI